Charted: Novo's promising results

Positive early-stage results for a new weight-loss treatment got Novo Nordisk investors excited today.

• The new treatment, amycretin, a weekly shot, delivered 22% weight loss over 36 weeks in Phase 1B/2A trials, compared with a 2% gain for patients on a placebo.

Why it matters: The Ozempic and Wegovy maker is trying to keep up in the feverish pharmaceutical race to deliver new treatments for obesity.

The impact: Novo's stock, which was up nearly 14% at one point in intraday trading, closed up 8.5% in the U.S.